Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation Sep 24, 2024 08:00AM
Nevro Announces Positive Coverage Update from Carelon Healthcare for the Treatment of Painful Diabetic Neuropathy Jan 18, 2024 04:15PM
Nevro to Highlight 25 Scientific Abstracts at 2024 North American Neuromodulation Society (NANS) Annual Meeting Jan 17, 2024 04:15PM
Nevro (NVRO) Reports Prelim Q4 Results Jan 9, 2024 08:31AM
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2023 Revenue Results Jan 9, 2024 08:30AM
View Older Stories

Jan 4, 2024 04:15PM Nevro to Present at 42nd Annual J.P. Morgan Healthcare Conference
Nov 30, 2023 05:19PM Nevro Announces Acquisition of Vyrsa™ Technologies
Nov 20, 2023 07:03AM Nevro (NVRO) announces publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain trial
Nov 20, 2023 07:00AM Nevro Delivers Long-Term Relief with High-Frequency Spinal Cord Stimulation: 24-Month Data Demonstrates Profound Improvements for Non-Surgical Refractory Back Pain
Nov 1, 2023 04:01PM Nevro Reports Third Quarter 2023 Financial Results, Provides Fourth Quarter Guidance and Updates Full-Year 2023 Guidance
Oct 4, 2023 07:00AM Nevro to Report Third Quarter 2023 Financial Results
Sep 18, 2023 07:00AM New Data Demonstrate the Health Economic Benefits of Nevro's High-Frequency Spinal Cord Stimulation Therapy
Aug 23, 2023 07:00AM Nevro Announces Participation in Upcoming Investor Conferences
Aug 16, 2023 07:04AM Nevro (NVRO) Announces New 24-Month Data Shows SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy
Aug 16, 2023 07:00AM New 24-Month Data Shows Nevro's SCS Therapy Provides Highly Effective, Long-Term Relief from Painful Diabetic Neuropathy
Aug 1, 2023 04:03PM Nevro Reports Second Quarter 2023 Financial Results, Provides Third Quarter Guidance and Updates Full-Year 2023 Guidance
Jul 13, 2023 07:00AM Nevro Announces Presentations at American Society of Pain & Neuroscience Fifth Annual Conference
Jul 12, 2023 07:00AM Nevro to Present at the Canaccord Genuity 43rd Annual Growth Conference
Jun 27, 2023 07:00AM Nevro to Report Second Quarter 2023 Financial Results
Jun 23, 2023 07:00AM Nevro Announces Painful Diabetic Neuropathy Clinical Data Presentations at the American Diabetes Association 83rd Scientific Sessions
Jun 5, 2023 04:05PM Nevro Names New Chief Commercial Officer
May 22, 2023 07:00AM Nevro to Present at Jefferies Healthcare Conference
Apr 27, 2023 04:05PM Nevro Corp. Announces New Employment Inducement Grant under Section 303A.08 of the NYSE Listed Company Manual
Apr 26, 2023 04:05PM Nevro Reports First Quarter 2023 Financial Results, Provides Second Quarter Guidance and Reiterates Full-Year 2023 Guidance
Apr 24, 2023 05:03PM Nevro Announces Enrollment of First Patient in PDN Sensory Study
Apr 24, 2023 07:00AM Nevro Announces Participation in Upcoming Investor Conferences
Apr 19, 2023 05:08PM Nevro (NVRO) Appoints Kevin Thornal as CEO and President
Apr 19, 2023 05:05PM Nevro Names Kevin Thornal as New Chief Executive Officer and President
Mar 29, 2023 07:00AM Nevro to Report First Quarter 2023 Financial Results
Mar 7, 2023 07:00AM Nevro Announces U.S. Full Market Launch of Revolutionary HFX iQ™ Spinal Cord Stimulation System to Personalize Treatment of Chronic Pain
Feb 23, 2023 04:05PM Nevro to Participate in Wells Fargo 2023 Medtech Innovation Spotlight Call Series
Feb 16, 2023 04:05PM Nevro Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides First Quarter and Complete Full-Year 2023 Guidance
Feb 1, 2023 07:00AM Nevro to Present at Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference
Jan 31, 2023 04:05PM Nevro Named to 2023 Bloomberg Gender-Equality Index for Second Consecutive Year
Jan 19, 2023 07:00AM Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results
Jan 12, 2023 07:00AM Nevro to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society (NANS) 26th Annual Meeting
Jan 9, 2023 06:04AM Nevro (NVRO) Guides Q4 Revenue of $113.8M, Provides FY23 Guidance
Jan 9, 2023 06:00AM Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance
Dec 19, 2022 04:05PM Nevro to Present at 41st Annual J.P. Morgan Healthcare Conference
Dec 14, 2022 07:00AM Nevro Announces Two Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2023 Annual Meeting
Nov 2, 2022 04:05PM Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy
Oct 13, 2022 04:31AM Nevro (NVRO) Announces FDA Approval of HFX iQ Spinal Cord Stimulation System
Oct 12, 2022 06:13PM Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain
Oct 10, 2022 07:04AM Nevro (NVRO) Comments on UnitedHealthcare Medical Coverage Policy Update
Oct 10, 2022 07:00AM Nevro Comments on UnitedHealthcare Medical Coverage Policy Update
Oct 5, 2022 07:00AM Nevro to Report Third Quarter 2022 Financial Results
Oct 4, 2022 04:05PM Nevro (NVRO) Granted FDA Approval of Costa Rica Manufacturing Operations
Oct 4, 2022 04:05PM Nevro Announces FDA Approval of Costa Rica Manufacturing Operations
Oct 3, 2022 07:00AM Nevro Announces American Association of Clinical Endocrinology Clinical Practice Guideline Has Been Updated to Include High-Frequency 10 kHz Spinal Cord Stimulation to Treat Painful Diabetic Neuropath
Sep 1, 2022 07:00AM Nevro Announces Multiple Positive Coverage Updates for the Treatment of Painful Diabetic Neuropathy
Aug 9, 2022 07:00AM Nevro Announces Participation In Upcoming Investor Conferences
Aug 3, 2022 04:05PM Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance
Aug 1, 2022 07:00AM Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations
Jul 21, 2022 07:00AM Nevro to Present at the Canaccord Genuity 42nd Annual Growth Conference
Jul 6, 2022 07:00AM Nevro to Report Second Quarter 2022 Financial Results
View Older Stories